IP Library Patent Application 14706165
Patent Application
App. No. 14/706,165

MULTILINEAGE STEM CELLS DERIVED FROM THE PERIPHERAL BLOOD AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/706,165
Abstract

The present invention discloses recovery and isolation of mesenchymal stem cells from the peripheral blood. This has an advantage of being able to obtain multilineage inducible cells from readily obtainable and autologous allogenic blood. With the present invention it is no longer necessary to depend on cadaver donor bone marrow, a technically complicated and an expensive process. Instead the patient may obtain the needed stem cells from a relatively small amount of his/her own blood, or from readily available blood donors.

Claims (26)

1 . A composition of isolated, post-natal, multilineage inducible, morphologically distinct cells from the peripheral blood which express at least CD90.

2 . The composition of claim 1 wherein the cells are isolated from a biological sample of the peripheral blood, human or animal.

3 . The composition of claim 1 wherein the cells do not express markers comprising HLADR and CD34 or high levels of CD45.

4 . The composition of claim 1 provided in a kit containing a defined and purified population of multilineage-inducible cells, the kit comprising:

a vial or container of the cells; and

a syringe for removing the cells from the vial or container for delivering the cells to a patient.

5 . A method of isolating post-natal, multilineage inducible, morphologically distinct cells from the peripheral blood which express at least CD90 inducing osteogenic or chondrogenic differentiation of a composition, comprising the steps of culturing of the multilineage induced cells in a chondrogenic medium including TBF beta 3, ascorbic acid, dexamethasone, sodium pyruvate, insulin, transferrin and glucose or in osteogenic medium.

6 . The method of claim 5 wherein the cells are grown on a thin bone plate with or without perforation.

7 . The method of claim 6 wherein cells are grown on decalcified thin bone plate.

8 . The method of claim 5 wherein the cells are contacted with freeze-dried, dried, dehydrated, frozen, cryopreserved or fresh particulate cartilage to induce chondrogenic differentiation.

9 . The method of claim 5 wherein the cells are contacted with dried, freeze-dried, dehydrated, frozen, cryopreserved or fresh particulate bone to induce osteogenic differentiation.

10 . The method of claim 5 wherein cells are contacted with freeze-dried, dried, dehydrated, frozen, or fresh particulate periosteum to induce osteogenic differentiation.

11 . The method of claim 5 wherein cells are contacted with freeze-dried, dried, dehydrated, frozen, cryopreserved or fresh particulate endosteum to effect osteogenic differentiation.

12 . The method of claim 5 wherein cells are placed in contact with freeze-dried, dried, dehydrated, frozen, cryopreserved or fresh particulate nervous tissue derived from the spinal cord, peripheral nerves or brain to effect neural differentiation.

13 . A method of treating a human patient-donor with cells from his or her own peripheral blood using a therapeutically effective amount of a composition of isolated, post-natal, multilineage inducible, morphologically distinct cells from the peripheral blood which express at least CD90 comprising the steps of:

extracting peripheral blood from the patient-donor to be treated;

isolating the cells from the peripheral blood which express at least CD90 marker;

acquiring a therapeutically effective amount of said cells for treating the patient-donor; and

treating said patient-donor with his or her isolated cells taken from the peripheral blood wherein said patient-donor has a nerve or orthopaedic bone or cartilage or connective tissue condition that is treated by the administration of the patient-donor isolated cells to induce repair of said condition.

14 . (canceled)

15 . (canceled)

16 . The method of claim 13 wherein the cells are contacted with freeze-dried, dried, dehydrated, frozen, cryopreserved or fresh particulate cartilage to induce chondrogenic differentiation.

17 . The method of claim 13 wherein the cells are contacted with, freeze-dried, dehydrated, cryopreserved or fresh particulate bone to induce osteogenic differentiation.

18 . The method of claim 13 wherein cells are contacted with freeze-dried, dried, dehydrated, frozen, or fresh particulate periosteum to induce osteogenic differentiation.

19 . The method of claim 13 wherein cells are contacted with freeze-dried, dried, dehydrated, frozen, cryopreserved or fresh particulate endosteum to effect osteogenic differentiation.

20 . The method of claim 13 wherein cells are placed in contact with freeze-dried, dried, dehydrated, frozen, cryopreserved or fresh particulate nervous tissue derived from the spinal cord, peripheral nerves or brain to effect neural differentiation.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Aug 29, 2022
From: BANKUNITED, N.A.
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 061333/0853 →
SECURITY INTEREST Recorded Aug 4, 2022
From: VIVEX BIOLOGICS GROUP, INC.
To: HERITAGE BANK OF COMMERCE
Reel/Frame 061084/0607 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2020
From: MALININ, THEODORE I.; MALININ, DOROTHY R.; WESTON, WENDY W.
To: VIVEX BIOMEDICAL, INC.
Reel/Frame 051856/0977 →
RELEASE OF SECURITY INTEREST Recorded Dec 12, 2019
From: HERITAGE BANK OF COMMERCE
To: VIVEX BIOMEDICAL, INC.; UMTB BIOMEDICAL, INC; ADVANCED NUMED TECHNOLOGIES, LTD.; VIVEX BIOMEDICAL INTERNATIONAL, INC.
Reel/Frame 051282/0653 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 11, 2019
From: VIVEX BIOLOGICS GROUP, INC.
To: BANKUNITED, N.A.
Reel/Frame 051260/0064 →
CHANGE OF NAME Recorded Aug 16, 2019
From: VIVEX BIOMEDICAL, INC.
To: VIVEX BIOLOGICS, INC.
Reel/Frame 050079/0179 →
CHANGE OF NAME Recorded Aug 16, 2019
From: VIVEX BIOLOGICS, INC.
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 050079/0225 →
SECURITY INTEREST Recorded Feb 22, 2017
From: VIVEX BIOMEDICAL, INC.; UMTB BIOMEDICAL, INC.; ADVANCED NUMED TECHNOLOGIES, LTD.; VIVEX BIOMEDICAL INTERNATIONAL, INC.
To: HERITAGE BANK OF COMMERCE
Reel/Frame 041782/0452 →